Cover Image
市場調查報告書

肺炎球菌疫苗的全球市場的未來展望 (到2020年)

Global Pneumonia Vaccine Market Outlook 2020

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 333058
出版日期 內容資訊 英文 50 Pages
訂單完成後即時交付
價格
Back to Top
肺炎球菌疫苗的全球市場的未來展望 (到2020年) Global Pneumonia Vaccine Market Outlook 2020
出版日期: 2015年06月01日 內容資訊: 英文 50 Pages
簡介

全球各國現在,10價肺炎球菌疫苗「PCV10」的開發有所進展,預期包含未接種疫苗的兒童,廣範圍地降低罹患率。其他也有各種疫苗、藥物的開發同時進行。全球的肺炎球菌疫苗的市場規模,2014年達到59億美元,推算2020年達到110億美元2014∼2020年的年複合成長率(CAGR) 為11.1%。現在美國、歐洲各國佔據市場大半,不過,在這個領域亞太地區各國也急速成長。

本報告提供全球的肺炎球菌疫苗市場最新趨勢與未來展望相關分析、疾病、藥物概要和目前普及、活用狀況、今後的藥物開發的方向性、市場趨勢預測 (今後6年份)、全球各國的管理體制,主要企業簡介與市場佔有率等調查評估。

第1章 分析師的見解

第2章 分析方法

第3章 肺炎鏈球菌感染和疫苗

第4章 全球肺炎球菌疫苗市場未來展望

  • 主要地區的市場

第5章 法規概要

  • 美國
  • 歐洲
  • 其他的國家
    • 印度
    • 中國
    • 日本

第6章 競爭力的評估

  • 主要企業的市場佔有率
  • 企業簡介
    • GlaxoSmithKline
      • 產業概要
      • 主要的財務指標
      • 優勢和弱點
    • Pfizer
    • Merck

圖表一覽

目錄

According to a new research, introduction of the 10-valent pneumococcal conjugate vaccine, PCV10, decreases the rates of clinical pneumonia even in unvaccinated children, a classic example of herd immunity. With a greater number of serotypes in current vaccines, there has been more disease reduction in both vaccinated and unvaccinated populations. As vaccines evolve, similar improvements can be expected.

According to our report, "Global Pneumonia Vaccine Market Outlook 2020", the Pneumonia vaccine market for 2014, which has been estimated at US$ 5.9 Billion, is expected to reach US$ 11 Billion by 2020, growing at a CAGR of 11.1% over the six year period. The report offers a clear and succinct take on the current Pneumococcal Vaccine Industry. The current market and future forecasts for the industry have been derived. The regional distribution of the current market has also been discussed. It has been noted that although USA and Europe are the major shareholders in the market, the developing regions are expected to account for a significant share too. This shift can be attributed to the rising incidences as well as the increasing purchasing power of the populations in these regions. Government's focus on a preventive healthcare strategy to cut down costs is also set to play a major role in the growth of the vaccine industry.

As vaccines are highly regulated to ensure patients and users have access to safe and effective medicines, the regulatory scenarios for vaccine approval and licensing has also been discussed. It has been noted that individual governments determine which products can be marketed in their countries and many have state-regulated systems governing product pricing.

Lastly, the report discusses the three major players in the industry viz., GlaxoSmithKline, Pfizer and Merck. The competitive landscape is supplemented with a chapter highlighting the current share of every player in the market. This is followed by company profiles, wherein the general business along with key financials of every player has been provided. At the end of every profile, a strength and weakness analysis has been performed. The report provides a prudent analysis of the market and is a must have supplement for any player interested in the industry.

Table of Contents

1. Analyst View

2. Research Methodology

3. Pneumococcal Disease and Vaccine

4. Global Pneumonia Vaccine Market Outlook 2020

  • 4.1 Key Geographical Markets

5. Regulatory Overview

  • 5.1 United States
  • 5.2 Europe
  • 5.3 Rest of the World
    • 5.3.1 India
    • 5.3.2 China
    • 5.3.3 Japan

6. Competitive Assessment

  • 6.1 Market Share of Major Players
  • 6.2 Company Profiles
    • 6.2.1 GlaxoSmithKline
      • 6.2.1.1 Business Overview
      • 6.2.1.2 Key Financials
      • 6.2.1.3 Strengths and Weaknesses
    • 6.2.2 Pfizer
      • 6.2.2.1 Business Overview
      • 6.2.2.2 Key Financials
      • 6.2.2.3 Strengths and Weaknesses
    • 6.2.3 Merck
      • 6.2.3.1 Business Overview
      • 6.2.3.2 Key Financials
      • 6.2.3.3 Strengths and Weaknesses

List of Figures:

  • Figure 4-1: Relation between Country Income and Under-5 Child Deaths from Pneumonia
  • Figure 4-2: Impact of Childhood Conjugate Pneumococcal Immunization on Incidence of Disease in < 5 Years of Age
  • Figure 4-3: Herd Immunity Impact of Childhood Pneumococcal Immunization in the US
  • Figure 4-4: Pneumonia Vaccine Market (Million US$), 2009-2014
  • Figure 4-5: Pneumonia Vaccine Market (Million Doses), 2009-2014
  • Figure 4-6: Pneumonia Vaccine Market (Million US$), 2014-2020
  • Figure 4-7: Pneumococcal Vaccine Market by Geography (%), 2014
  • Figure 4-8: Percentage of Adults Aged 65 and over who had ever received a Pneumococcal Vaccination: United States, 1997-2013
  • Figure 4-9: Age-Adjusted Death Rates for Pneumonia in 2013: United States, 1999-2013
  • Figure 6-1: Pneumococcal Vaccine Market Value Share by Players (%), 2014
  • Figure 6-2: Pneumococcal Vaccine Market Volume Share by Players (%), 2014
  • Figure 6-3: GSK - Revenue by Geographic Segment (%), 2014
  • Figure 6-4: GSK - Revenue by Business Segment (%), 2014
  • Figure 6-5: GSK - Break-up of Revenue of Pharmaceutical and Vaccines Business Segment (%), 2014
  • Figure 6-6: GSK - Synflorix Sales (Million GBP), 2010-2014
  • Figure 6-7: Pfizer - Revenue by Geography (%), 2014
  • Figure 6-8: Pfizer - Revenue by Business Segment (%), 2014
  • Figure 6-9: Pfizer - Prevnar Family Sales (Million USD), 2010-2014
  • Figure 6-10: Merck - Revenue by Business Segment (%), 2014
  • Figure 6-11: Merck - Revenue by Geography (%), 2014
  • Figure 6-12: Merck - Pneumovax 23 Sales (Million USD), 2010-2014

List of Tables:

  • Table 4-1: Current levels of coverage for interventions that prevent (vaccination) Pneumonia
  • Table 6-1: GSK - Pneumonia Vaccine Portfolio
  • Table 6-2: GSK - Key Financials (Million GBP), 2012-2014
  • Table 6-3: GSK - Strengths and Weaknesses
  • Table 6-4: Pfizer - Pneumonia Vaccine Portfolio
  • Table 6-5: Pfizer - Key Financials (Million US$), 2012-2014
  • Table 6-6: Pfizer - Strengths and Weaknesses
  • Table 6-7: Merck - Pneumonia Vaccine Portfolio
  • Table 6-8: Merck - Key Financials (Millions US$), 2012-2014
  • Table 6-9: Merck - Strengths and Weaknesses
Back to Top